O. Bouché

460 total citations
26 papers, 261 citations indexed

About

O. Bouché is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, O. Bouché has authored 26 papers receiving a total of 261 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 9 papers in Surgery and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in O. Bouché's work include Colorectal Cancer Treatments and Studies (11 papers), Cancer Treatment and Pharmacology (9 papers) and Lung Cancer Treatments and Mutations (6 papers). O. Bouché is often cited by papers focused on Colorectal Cancer Treatments and Studies (11 papers), Cancer Treatment and Pharmacology (9 papers) and Lung Cancer Treatments and Mutations (6 papers). O. Bouché collaborates with scholars based in France. O. Bouché's co-authors include Jean‐Luc Raoul, Laurent Bedenne, Franck Bonnetain, Philippe Rougier, F. Masskouri, N. Dupouy, Jean‐Pierre Pignon, Laëtitia Dahan, Valérie Boige and Michel Ducreux and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

O. Bouché

25 papers receiving 254 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
O. Bouché France	8	138	125	72	62	59	26	261
Jean Didier Grangè France	6	133 1.0×	100 0.8×	57 0.8×	29 0.5×	173 2.9×	18	314
Vikas Ostwal India	9	158 1.1×	37 0.3×	81 1.1×	58 0.9×	90 1.5×	63	273
P. Stübs Germany	9	152 1.1×	150 1.2×	170 2.4×	117 1.9×	71 1.2×	19	339
Olga Kozyreva United States	10	146 1.1×	50 0.4×	98 1.4×	96 1.5×	47 0.8×	46	244
Cheng‐Chung Tsai Taiwan	9	82 0.6×	179 1.4×	170 2.4×	90 1.5×	104 1.8×	16	322
Eric E. Elliott United States	9	192 1.4×	113 0.9×	169 2.3×	161 2.6×	83 1.4×	12	342
Masaki Munakata Japan	9	217 1.6×	43 0.3×	92 1.3×	156 2.5×	33 0.6×	39	320
Suzanne Darby United Kingdom	7	117 0.8×	111 0.9×	158 2.2×	217 3.5×	88 1.5×	14	404
Qinglong Jiang China	11	173 1.3×	45 0.4×	121 1.7×	120 1.9×	38 0.6×	16	247
Azra Husić-Selimović Bosnia and Herzegovina	7	63 0.5×	26 0.2×	63 0.9×	32 0.5×	35 0.6×	27	208

Countries citing papers authored by O. Bouché

Since Specialization

Citations

This map shows the geographic impact of O. Bouché's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by O. Bouché with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites O. Bouché more than expected).

Fields of papers citing papers by O. Bouché

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by O. Bouché. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by O. Bouché. The network helps show where O. Bouché may publish in the future.

Co-authorship network of co-authors of O. Bouché

This figure shows the co-authorship network connecting the top 25 collaborators of O. Bouché. A scholar is included among the top collaborators of O. Bouché based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with O. Bouché. O. Bouché is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Borg, Christophe, V. Vendrely, Thierry André, et al.. (2023). 651P DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: A multicenter propensity score matching study. Annals of Oncology. 34. S456–S457. 1 indexed citations

Rullier, Anne, C. Mariette, E. Maillard, et al.. (2017). Neoadjuvant FOLFOX 4 versus FOLFOX 4 plus cetuximab versus immediate surgery for high-risk stage II and III colon cancers: A phase II multicentre randomised controlled trial (PRODIGE 22). Annals of Oncology. 28. v159–v159. 1 indexed citations

Lepage, Côme, Laurent Cany, E. Maillard, et al.. (2016). Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer - PRODIGE 13 a FFCD and Unicancer phase III trial: baseline characteristics. Annals of Oncology. 27. vi159–vi159. 3 indexed citations

Aparicio, Thomas, O. Bouché, Éric François, et al.. (2016). Prognostic factor analysis for elderly patients treated for metastatic colorectal cancer in the randomized phase II trial PRODIGE 20. Annals of Oncology. 27. vi194–vi194. 1 indexed citations

Samalin, Emmanuelle, O. Bouché, Simon Thézenas, et al.. (2011). 6091 POSTER Final Results of a Multicentre Phase II Trial Assessing Sorafenib in Combination With Irinotecan as 2nd or Later-line Treatment in Metastatic Colorectal Cancer (mCRC) Patients With KRas Mutated Tumours (mt) (NEXIRI). European Journal of Cancer. 47. S418–S418. 2 indexed citations

Aparicio, Thomas, L. Teillet, D. Gargot, et al.. (2011). Geriatric factors to predict toxicity and dose-intensity reduction in FFCD 2001-02 phase III study comparing a first-line chemotherapy of LV5FU2 or FOLFIRI in treatment of metastatic colorectal cancer (mCRC) in elderly patients.. Journal of Clinical Oncology. 29(15_suppl). 9111–9111. 1 indexed citations

Cutsem, Eric Van, Hans Prenen, Carmen Guillén‐Ponce, et al.. (2011). A Phase l/lI, Open-label, Randomised Study of BIBF 1120 Plus mFOLFOX6 Compared to Bevacizumab Plus mFOLFOX6 in Patients with Metastatic Colorectal Cancer. European Journal of Cancer. 47. 8–9. 19 indexed citations

Ychou, Marc, Emmanuel Jean Francois, Simon Thézenas, et al.. (2010). Sorafenib (S) in combination with irinotecan (I) as a treatment in metastatic colorectal cancer (mCRC) patients (pts) with KRAS mutation (mt) as second line or later: Interim analysis results of multicenter phase II part trial (NEXIRI).. Journal of Clinical Oncology. 28(15_suppl). e14022–e14022. 2 indexed citations

Bonnetain, Franck, Xavier Paolettí, Sandra Collette, et al.. (2008). Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trials. Quality of Life Research. 17(6). 831–843. 54 indexed citations

10.

Merlin, J.L., Géraldine Perkins, Astrid Lièvre, et al.. (2008). Additional value of EGFR downstream signaling phosphoprotein expression to KRAS mutation for response prediction to cetuximab in colorectal cancer (CRC). Journal of Clinical Oncology. 26(15_suppl). 4126–4126. 5 indexed citations

11.

Boige, Valérie, Jean‐Luc Raoul, Jean‐Pierre Pignon, et al.. (2007). Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. British Journal of Cancer. 97(7). 862–867. 66 indexed citations

12.

Chauffert, Bruno, F. Mornex, Franck Bonnetain, et al.. (2006). Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: A FFCD-SFRO study. Journal of Clinical Oncology. 24(18_suppl). 4008–4008. 34 indexed citations

13.

Ychou, Marc, et al.. (2006). [Recommendations for clinical practice: management of stomach adenocarcinoma].. PubMed. 93(2). 192–6. 2 indexed citations

14.

Bouché, O., Franck Bonnetain, Catherine Lombard‐Bohas, et al.. (2005). Treatment of advanced hepatocellular carcinoma with long-acting octreotide: preliminary results of a randomized placebo-controlled trial (FFCD-ANGH 2001–01 CHOC). Journal of Clinical Oncology. 23(16_suppl). 4036–4036. 8 indexed citations

15.

Cadiot, Guillaume, Corinne Merle, Damien Jolly, et al.. (2001). Bleeding reflux esophagitis: a prospective 1-year study in a university hospital. The American Journal of Gastroenterology. 96(1). 47–51. 12 indexed citations

16.

Desoize, B, et al.. (1999). Puzzles in the clinical pharmacokinetics of fluorouracil.. PubMed. 18(6B). 4607–10. 6 indexed citations

17.

Zeitoun, P, et al.. (1998). Outcome of erosive/ulcerative reflux oesophagitis in 181 consecutive patients 5 years after diagnosis.. PubMed. 30(5). 470–4. 6 indexed citations

18.

Bouché, O.. (1996). Faut-il éradiquer Helicobacter pylori chez un malade ayant une gastrite chronique?. Gastroentérologie Clinique et Biologique. 20. 1 indexed citations

19.

Abdelli, Naceur, et al.. (1996). [Primary leiomyosarcoma of the liver 37 years after successful treatment of hereditary retinoblastoma].. PubMed. 20(5). 502–5. 13 indexed citations

20.

Bouché, O., et al.. (1993). [Is there still a place for surgery in the treatment of communicating pseudocyst in chronic pancreatitis?].. PubMed. 47(4). 331–40; discussion 341. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact